Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Greenberg, P. A.
Right arrow Articles by Buzdar, A. U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Greenberg, P. A.
Right arrow Articles by Buzdar, A. U.

Journal of Clinical Oncology, Vol 14, 2197-2205, Copyright © 1996 by American Society of Clinical Oncology

ARTICLES

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer

PA Greenberg, GN Hortobagyi, TL Smith, LD Ziegler, DK Frye and AU Buzdar
Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, USA.

PURPOSE: To determine the long-term clinical course of patients with metastatic breast cancer (MBC) who achieved a complete remission with doxorubicin-alkylating agent-containing combination chemotherapy programs. PATIENTS AND METHODS: To assess the long-term prognosis of MBC, we reviewed our experience with 1,581 patients treated on consecutive doxorubicin and alkylating agent-containing front-line treatment protocols between 1973 and 1982. Treatment was administered for a maximum duration of 2 years. Characteristics of long-term survivors were evaluated, and hazard rates for progression were calculated. RESULTS: From this group, 263 (16.6%) achieved complete responses (CR) and 49 (3.1%) remained in CR for more than 5 years. After a median duration of 191 months, 26 patients remain in first CR, four patients died in CR at times ranging from 118 to 234 months, 18 patients died of breast cancer, and one is alive with metastatic disease. Compared with the overall CR and total patient populations, the long-term CR group had more premenopausal patients, a younger median age, a lower tumor burden, and better performance status. The hazard function shows a substantial drop in risk of progression after approximately 3 years from initiation of therapy. Ten long-term CR patients developed second primary cancers: breast (3), ovary (2), pancreas (1), endometrium (1), colon (1), head and neck (1), and lung (1). CONCLUSION: Most patients with MBC treated with systemic therapies have only temporary responses to treatment, but some patients continue in CR following initial treatment. These data show that a small percentage of patients achieve long-term remissions with standard chemotherapy regimens. Remission consolidation strategies are needed.


This article has been cited by other articles:


Home page
 Ann OncolHome page
M. Cristofanilli, P. Morandi, S. Krishnamurthy, J. M. Reuben, B.-N. Lee, D. Francis, D. J. Booser, M. C. Green, B. K. Arun, L. Pusztai, et al.
Imatinib mesylate (Gleevec(R)) in advanced breast cancer-expressing C-Kit or PDGFR-{beta}: clinical activity and biological correlations
Ann. Onc., May 29, 2008; (2008) mdn352v1.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. Vultur, R. Buettner, C. Kowolik, W. Liang, D. Smith, F. Boschelli, and R. Jove
SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells
Mol. Cancer Ther., May 1, 2008; 7(5): 1185 - 1194.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Crump, S. Gluck, D. Tu, D. Stewart, M. Levine, P. Kirkbride, J. Dancey, S. O'Reilly, T. Shore, S. Couban, et al.
Randomized Trial of High-Dose Chemotherapy With Autologous Peripheral-Blood Stem-Cell Support Compared With Standard-Dose Chemotherapy in Women With Metastatic Breast Cancer: NCIC MA.16
J. Clin. Oncol., January 1, 2008; 26(1): 37 - 43.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Colozza, E. de Azambuja, N. Personeni, F. Lebrun, M. J. Piccart, and F. Cardoso
Achievements in Systemic Therapies in the Pregenomic Era in Metastatic Breast Cancer
Oncologist, March 1, 2007; 12(3): 253 - 270.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
N. Rucci, I. Recchia, A. Angelucci, M. Alamanou, A. Del Fattore, D. Fortunati, M. Susa, D. Fabbro, M. Bologna, and A. Teti
Inhibition of Protein Kinase c-Src Reduces the Incidence of Breast Cancer Metastases and Increases Survival in Mice: Implications for Therapy
J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 161 - 172.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
J. B Engel, A. V Schally, G. Halmos, B. Baker, A. Nagy, and G. Keller
Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins
Endocr. Relat. Cancer, December 1, 2005; 12(4): 999 - 1009.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
E. C. McLemore, B. A. Pockaj, C. Reynolds, R. J. Gray, J. L. Hernandez, C. S. Grant, and J. H. Donohue
Breast Cancer: Presentation and Intervention in Women With Gastrointestinal Metastasis and Carcinomatosis
Ann. Surg. Oncol., November 1, 2005; 12(11): 886 - 894.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. O'Shaughnessy
Extending Survival with Chemotherapy in Metastatic Breast Cancer
Oncologist, October 1, 2005; 10(suppl_3): 20 - 29.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. K. Ibrahim, B. Samuels, R. Page, D. Doval, K. M. Patel, S.C. Rao, M. K. Nair, P. Bhar, N. Desai, and G. N. Hortobagyi
Multicenter Phase II Trial of ABI-007, an Albumin-Bound Paclitaxel, in Women With Metastatic Breast Cancer
J. Clin. Oncol., September 1, 2005; 23(25): 6019 - 6026.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Bruzzi, L. Del Mastro, M. P. Sormani, L. Bastholt, M. Danova, C. Focan, G. Fountzilas, J. Paul, R. Rosso, and M. Venturini
Objective Response to Chemotherapy As a Potential Surrogate End Point of Survival in Metastatic Breast Cancer Patients
J. Clin. Oncol., August 1, 2005; 23(22): 5117 - 5125.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Zielinski, S. Beslija, Z. Mrsic-Krmpotic, M. Welnicka-Jaskiewicz, C. Wiltschke, Z. Kahan, M. Grgic, V. Tzekova, M. Inbar, J. Cervek, et al.
Gemcitabine, Epirubicin, and Paclitaxel Versus Fluorouracil, Epirubicin, and Cyclophosphamide As First-Line Chemotherapy in Metastatic Breast Cancer: A Central European Cooperative Oncology Group International, Multicenter, Prospective, Randomized Phase III Trial
J. Clin. Oncol., March 1, 2005; 23(7): 1401 - 1408.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Cristofanilli, D. F. Hayes, G. T. Budd, M. J. Ellis, A. Stopeck, J. M. Reuben, G. V. Doyle, J. Matera, W. J. Allard, M. C. Miller, et al.
Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer
J. Clin. Oncol., March 1, 2005; 23(7): 1420 - 1430.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. D. Miller, L. I. Chap, F. A. Holmes, M. A. Cobleigh, P. K. Marcom, L. Fehrenbacher, M. Dickler, B. A. Overmoyer, J. D. Reimann, A. P. Sing, et al.
Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer
J. Clin. Oncol., February 1, 2005; 23(4): 792 - 799.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Schmid, W. Schippinger, T. Nitsch, G. Huebner, V. Heilmann, W. Schultze, H. Hausmaninger, M. Wischnewsky, and K. Possinger
Up-Front Tandem High-Dose Chemotherapy Compared With Standard Chemotherapy With Doxorubicin and Paclitaxel in Metastatic Breast Cancer: Results of a Randomized Trial
J. Clin. Oncol., January 20, 2005; 23(3): 432 - 440.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. Bernard-Marty, F. Cardoso, and M. J. Piccart
Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer
Oncologist, November 1, 2004; 9(6): 617 - 632.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
R. C. F. Leonard, M. Lind, C. Twelves, R. Coleman, S. van Belle, C. Wilson, J. Ledermann, I. Kennedy, P. Barrett-Lee, T. Perren, et al.
Conventional Adjuvant Chemotherapy Versus Single-Cycle, Autograft-Supported, High-Dose, Late-Intensification Chemotherapy in High-Risk Breast Cancer Patients: A Randomized Trial
J Natl Cancer Inst, July 21, 2004; 96(14): 1076 - 1083.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Alba, M. Martin, M. Ramos, E. Adrover, A. Balil, C. Jara, A. Barnadas, A. Fernandez-Aramburo, P. Sanchez-Rovira, M. Amenedo, et al.
Multicenter Randomized Trial Comparing Sequential With Concomitant Administration of Doxorubicin and Docetaxel As First-Line Treatment of Metastatic Breast Cancer: A Spanish Breast Cancer Research Group (GEICAM-9903) Phase III Study
J. Clin. Oncol., July 1, 2004; 22(13): 2587 - 2593.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
W. J. Gradishar
Tamoxifen--What Next?
Oncologist, July 1, 2004; 9(4): 378 - 384.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Alexopoulos, M. V. Karamouzis, H. Stavrinides, A. Ardavanis, K. Kandilis, J. Stavrakakis, C. Georganta, and G. Rigatos
Phase II study of pegylated liposomal doxorubicin (Caelyx(R)) and docetaxel as first-line treatment in metastatic breast cancer
Ann. Onc., June 1, 2004; 15(6): 891 - 895.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S.-C. J. Lin, K.-F. Lee, A. Yu. Nikitin, S. G. Hilsenbeck, R. D. Cardiff, A. Li, K.-W. Kang, S. A. Frank, W.-H. Lee, and E. Y-H. P. Lee
Somatic Mutation of p53 Leads to Estrogen Receptor {alpha}-Positive and -Negative Mouse Mammary Tumors with High Frequency of Metastasis
Cancer Res., May 15, 2004; 64(10): 3525 - 3532.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. T. Chung and R. W. Carlson
Goals and Objectives in the Management of Metastatic Breast Cancer
Oncologist, December 1, 2003; 8(6): 514 - 520.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Lapillonne, M. Konopleva, T. Tsao, D. Gold, T. McQueen, R. L. Sutherland, T. Madden, and M. Andreeff
Activation of Peroxisome Proliferator-activated Receptor {gamma} by a Novel Synthetic Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic Acid Induces Growth Arrest and Apoptosis in Breast Cancer Cells
Cancer Res., September 15, 2003; 63(18): 5926 - 5939.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. E. Singletary, G. Walsh, J.-N. Vauthey, S. Curley, R. Sawaya, K. L. Weber, F. Meric, and G. N. Hortobagyi
A Role for Curative Surgery in the Treatment of Selected Patients with Metastatic Breast Cancer
Oncologist, June 1, 2003; 8(3): 241 - 251.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. Valero and G. N. Hortobagyi
Are Anthracycline-Taxane Regimens the New Standard of Care in the Treatment of Metastatic Breast Cancer?
J. Clin. Oncol., March 15, 2003; 21(6): 959 - 962.
[Full Text] [PDF]

Home page
 JCOHome page
J.-M. Nabholtz, C. Falkson, D. Campos, J. Szanto, M. Martin, S. Chan, T. Pienkowski, J. Zaluski, T. Pinter, M. Krzakowski, et al.
Docetaxel and Doxorubicin Compared With Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III Trial
J. Clin. Oncol., March 15, 2003; 21(6): 968 - 975.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. J. Esteva, J. Glaspy, S. Baidas, L. Laufman, L. Hutchins, M. Dickler, D. Tripathy, R. Cohen, A. DeMichele, R. C. Yocum, et al.
Multicenter Phase II Study of Oral Bexarotene for Patients With Metastatic Breast Cancer
J. Clin. Oncol., March 15, 2003; 21(6): 999 - 1006.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. Overmoyer
Combination Chemotherapy for Metastatic Breast Cancer: Reaching for the Cure
J. Clin. Oncol., February 15, 2003; 21(4): 580 - 582.
[Full Text] [PDF]

Home page
 Ann OncolHome page
E. Heidemann, H. Stoeger, R. Souchon, W.-D. Hirschmann, H. Bodenstein, C. Oberhoff, J. T. Fischer, M. Schulze, M. Clemens, R. Andreesen, et al.
Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial
Ann. Onc., November 1, 2002; 13(11): 1717 - 1729.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Osoba, D. J. Slamon, M. Burchmore, and M. Murphy
Effects on Quality of Life of Combined Trastuzumab and Chemotherapy in Women With Metastatic Breast Cancer
J. Clin. Oncol., July 15, 2002; 20(14): 3106 - 3113.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
P. BRUZZI
Objective Response to Treatment as a Potential Surrogate Marker of Survival in Breast Cancer
Ann. N.Y. Acad. Sci., June 1, 2002; 963(1): 144 - 147.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Vici, G. Colucci, V. Gebbia, A. Amodio, F. Giotta, F. Belli, F. Conti, N. Gebbia, G. Pezzella, M. R. Valerio, et al.
First-Line Treatment With Epirubicin and Vinorelbine in Metastatic Breast Cancer
J. Clin. Oncol., June 1, 2002; 20(11): 2689 - 2694.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Pawlicki, J. Rolski, J. Zaluski, P. Siedlecki, C. Ramlau, and P. Tomzak
A Phase II Study of Intravenous Navelbine and Doxorubicin Combination in Previously Untreated Advanced Breast Carcinoma
Oncologist, June 1, 2002; 7(3): 205 - 209.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Schneeweiss, M. Hensel, P. Sinn, T. Khbeis, R. Haas, G. Bastert, and A. D. Ho
Characteristics associated with long-term progression-free survival following high-dose chemotherapy in metastatic breast cancer and influence of chemotherapy dose
Ann. Onc., May 1, 2002; 13(5): 679 - 688.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Venturini, L. Del Mastro, O. Garrone, C. Angiolini, M. Merlano, M. Bergaglio, G. Tolino, A. Lambiase, A. Baldini, G. Canavese, et al.
Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer
Ann. Onc., April 1, 2002; 13(4): 546 - 552.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
F. Cardoso, A. Di Leo, C. Lohrisch, C. Bernard, F. Ferreira, and M. J. Piccart
Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?
Ann. Onc., February 20, 2002; 13(2): 197 - 207.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. N. Hortobagyi
Can We Cure Limited Metastatic Breast Cancer?
J. Clin. Oncol., February 1, 2002; 20(3): 620 - 623.
[Full Text] [PDF]

Home page
 JCOHome page
Y. Nieto, S. Nawaz, R. B. Jones, E. J. Shpall, P. J. Cagnoni, P. A. McSweeney, A. Baron, C. Razook, S. Matthes, and S. I. Bearman
Prognostic Model for Relapse After High-Dose Chemotherapy With Autologous Stem-Cell Transplantation for Stage IV Oligometastatic Breast Cancer
J. Clin. Oncol., February 1, 2002; 20(3): 707 - 718.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. A. Lawrence, P. C. Adamson, R. Caruso, C. Chow, D. Kleiner, R. F. Murphy, D. J. Venzon, M. Shovlin, M. Noone, M. Merino, et al.
Phase I Clinical Trial of Alitretinoin and Tamoxifen in Breast Cancer Patients: Toxicity, Pharmacokinetic, and Biomarker Evaluations
J. Clin. Oncol., May 15, 2001; 19(10): 2754 - 2763.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
F. J. Esteva, V. Valero, L. Pusztai, L. Boehnke-Michaud, A. U. Buzdar, and G. N. Hortobagyi
Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and Beyond
Oncologist, April 1, 2001; 6(2): 133 - 146.
[Abstract] [Full Text]

Home page
 JCOHome page
J. Jassem, T. Pienkowski, A. Pluzanska, S. Jelic, V. Gorbunova, Z. Mrsic-Krmpotic, J. Berzins, T. Nagykalnai, N. Wigler, J. Renard, et al.
Doxorubicin and Paclitaxel Versus Fluorouracil, Doxorubicin, and Cyclophosphamide as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomized Phase III Multicenter Trial
J. Clin. Oncol., March 15, 2001; 19(6): 1707 - 1715.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, et al.
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
N. Engl. J. Med., March 15, 2001; 344(11): 783 - 792.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. A. Brito, V. Valero, A. U. Buzdar, D. J. Booser, F. Ames, E. Strom, M. Ross, R. L. Theriault, D. Frye, S.-W. Kau, et al.
Long-Term Results of Combined-Modality Therapy for Locally Advanced Breast Cancer With Ipsilateral Supraclavicular Metastases: The University of Texas M.D. Anderson Cancer Center Experience
J. Clin. Oncol., February 1, 2001; 19(3): 628 - 633.
[Abstract] [Full Text] [PDF]

Home page
 Stem CellsHome page
A. Schneeweiss, M. Hensel, R. Goerner, T. Khbeis, S. Hohaus, G. Egerer, E. Solomayer, R. Haas, E.-M. Grischke, G. Bastert, et al.
Comparison of Double and Triple High-Dose Chemotherapy with Autologous Blood Stem Cell Transplantation in Patients with Metastatic Breast Cancer
Stem Cells, February 1, 2001; 19(2): 151 - 160.
[Abstract] [Full Text]

Home page
 JCOHome page
M. Ando, T. Watanabe, K. Nagata, M. Narabayashi, I. Adachi, and N. Katsumata
Efficacy of Docetaxel 60 mg/m2 in Patients With Metastatic Breast Cancer According to the Status of Anthracycline Resistance
J. Clin. Oncol., January 15, 2001; 19(2): 336 - 342.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Rodenhuis
The Status of High-Dose Chemotherapy in Breast Cancer
Oncologist, October 1, 2000; 5(5): 369 - 375.
[Abstract] [Full Text]

Home page
 JCOHome page
Epirubicin-Based Chemotherapy in Metastatic Breast Cancer Patients: Role of Dose-Intensity and Duration of Treatment
J. Clin. Oncol., September 17, 2000; 18(17): 3115 - 3124.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. Tempfer, M. Seifert, T. Brodowicz, L. Auerbach, C. Zielinski, P. Iacopino, S. Palazzo, F. Patrone, E. A. Stadtmauer, L. J. Goldstein, et al.
High-Dose Chemotherapy plus Hematopoietic Stem-Cell Rescue for Metastatic Breast Cancer
N. Engl. J. Med., August 10, 2000; 343(6): 439 - 441.
[Full Text]

Home page
 Clin. Cancer Res.Home page
T. Gilewski, S. Adluri, G. Ragupathi, S. Zhang, T.-J. Yao, K. Panageas, M. Moynahan, A. Houghton, L. Norton, and P. O. Livingston
Vaccination of High-Risk Breast Cancer Patients with Mucin-1 (MUC1) Keyhole Limpet Hemocyanin Conjugate plus QS-21
Clin. Cancer Res., May 1, 2000; 6(5): 1693 - 1701.
[Abstract] [Full Text]

Home page
 NEJMHome page
E. A. Stadtmauer, A. O'Neill, L. J. Goldstein, P. A. Crilley, K. F. Mangan, J. N. Ingle, I. Brodsky, S. Martino, H. M. Lazarus, J. K. Erban, et al.
Conventional-Dose Chemotherapy Compared with High-Dose Chemotherapy plus Autologous Hematopoietic Stem-Cell Transplantation for Metastatic Breast Cancer
N. Engl. J. Med., April 13, 2000; 342(15): 1069 - 1076.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Alexandre, P. Bleuzen, J. Bonneterre, W. Sutherland, J. L. Misset, J.-P. Guastalla, P. Viens, S. Faivre, A. Chahine, M. Spielman, et al.
Factors Predicting for Efficacy and Safety of Docetaxel in a Compassionate-Use Cohort of 825 Heavily Pretreated Advanced Breast Cancer Patients
J. Clin. Oncol., February 1, 2000; 18(3): 562 - 562.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. B. Weiss
The Randomized Trials of Dose-Intensive Therapy for Breast Cancer: What Do They Mean for Patient Care and Where Do We Go From Here?
Oncologist, December 1, 1999; 4(6): 450 - 458.
[Abstract] [Full Text]

Home page
 JAMAHome page
K. H. Antman, D. F. Heitjan, and G. N. Hortobagyi
High-Dose Chemotherapy for Breast Cancer
JAMA, November 10, 1999; 282(18): 1701 - 1703.
[Full Text] [PDF]

Home page
 JCOHome page
A. Gennari, B. Salvadori, S. Donati, C. Bengala, C. Orlandini, R. Danesi, M. Del Tacca, P. Bruzzi, and P. F. Conte
Cardiotoxicity of Epirubicin/Paclitaxel-Containing Regimens: Role of Cardiac Risk Factors
J. Clin. Oncol., November 1, 1999; 17(11): 3596 - 3602.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Livingston and J. Crowley
Commentary on PBT-1 Study of High-Dose Consolidation Versus Standard Therapy in Metastatic Breast Cancer
J. Clin. Oncol., November 1, 1999; 17(90001): 22 - 24.
[Full Text] [PDF]

Home page
 JAMAHome page
P. A. Rowlings, S. F. Williams, K. H. Antman, K. K. Fields, J. W. Fay, E. Reed, C. J. Pelz, J. P. Klein, K. A. Sobocinski, M. J. Kennedy, et al.
Factors Correlated With Progression-Free Survival After High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Metastatic Breast Cancer
JAMA, October 13, 1999; 282(14): 1335 - 1343.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. A. Rizzieri, J. J. Vredenburgh, R. Jones, M. Ross, E. J. Shpall, A. Hussein, G. Broadwater, D. Berry, W. P. Petros, C. Gilbert, et al.
Prognostic and Predictive Factors for Patients With Metastatic Breast Cancer Undergoing Aggressive Induction Therapy Followed by High-Dose Chemotherapy With Autologous Stem-Cell Support
J. Clin. Oncol., October 1, 1999; 17(10): 3064 - 3074.
[Abstract] [Full Text] [PDF]